title: Latanoprost-induced prostaglandin-associated periorbitopathy.
abstract: OBJECTIVE
  To report, with supporting photo-documentation, cases of latanoprost-induced prostaglandin-associated periorbitopathy (PAP).
  
  
  METHODS
  Retrospective small case series with three cases. Chart review with photo-documentation of clinical features of prostaglandin-associated periorbitopathy resulting from latanoprost use. Patients developed involution of dermatochalasia, blepharoptosis, deepening of orbital sulci, and flattening of lower eyelid bags after a mean usage period of 6 years (3 to 8 years).
  
  
  CONCLUSIONS
  Latanoprost can cause PAP, although it has a lower risk and longer latency of onset than those with bimatoprost and travoprost. Clinicians should be aware of this side effect and monitor for signs periodically. Chronic unilateral prostaglandin use may cause unfavorable asymmetry in the appearance of the periorbital area.
authors.affiliation: Nassau University Medical Center, East Meadow, Westbury, NY, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Tan
authors.forename: Stanley
authors.initials: S
authors.lastname: Berke
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects*; D001763:Blepharoptosis / Q000139:chemically induced; D003483:Cutis Laxa / Q000139:chemically induced; D005141:Eyelid Diseases / Q000139:chemically induced*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D006801:Humans; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009916:Orbital Diseases / Q000139:chemically induced*; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects*; D012189:Retrospective Studies
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost